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Abstract 
Congenital bladder neck obstruction (or lower urinary tract obstruction [LUTO]) 
describes a heterogeneous group of congenital anomalies presenting with similar 
prenatal ultrasonographic findings of dilated posterior urethra, megacystis, 
hydronephrosis, oligohydramnios and often with associated renal dysplasia. 
Untreated LUTO has high rate of perinatal morbidity and mortality from 
associated pulmonary hypoplasia and early-onset renal failure in infancy. 
Ultrasonographic features and prospective fetal urinalysis may help in predicting 
the overall prognosis of congenital LUTO. Currently, fetal vesicoamniotic shunt 
(of various designs), and fetal cystoscopy and fulguration of the obstruction are 
potential prenatal interventions. Retrospective and prospective cohort studies 
and a relatively small randomized controlled trial have demonstrated these 
treatments may possibly improve perinatal survival. Despite this, concerns 
remain as to the high rates of renal impairment observed in paediatric survivors. 
A clinical prospective scoring / staging system may improve prenatal diagnostic 
criteria and case selection for fetal therapy. 
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I) Introduction. 
The use of prenatal ultrasonography in routine pregnancy screening allows 
detection of fetal anomalies. Congenital renal and urinary tract anomaly 
constitutes approximately 21% of all congenital abnormalities (1) with a 
reported incidence of 1:250-1,000 pregnancies (2). In the latest report of UK 
renal registry in 2015, obstructive uropathy was the second most common 
underlying aetiology (19%) leading to end stage renal failure under the age of 16 
years (3). The condition of congenital bladder neck obstruction is associated 
with a perinatal mortality rate of up to 45% for untreated cases (4) with 
approximately 30% developing end stage renal failure requiring paediatric 
dialysis and renal transplantation before the age of 5 years (5). Overall, 
childhood survival has been reported as being lowest for the cohort of patients 
starting renal dialysis or requiring transplantation before two years of age 
(hazard ratio of 4.1) when compared to the 12–16 years age group (3). Due to the 
high associated fetal and perinatal mortality with associated long-term morbidity 
in survivors there is enthusiasm for in-utero intervention in an attempt to modify 
the natural pathogenesis of congenital obstructive uropathy. However, this 
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should ideally not just ameliorate fetal and neonatal morbidity, but also long 
term renal and systemic impairment.  
 
II) Prevalence and pathology 
Congenital lower urinary tract obstruction (LUTO) describes a heterogenous 
group of anatomical uropathies with pathology primarily affecting the bladder 
neck or urethra. Population-based studies from Regional Congenital Anomaly 
Registers in the UK estimate prevalence of congenital lower urinary tract 
obstruction (LUTO) at between 2.2-3.3 per 10,000 births (6, 7). From these 
epidemiological studies, it appears that posterior urethral valves are the most 
common underlying pathology in LUTO (63%) (6,7), followed by urethral atresia 
(or stenosis) (17% of cases) (7). The male fetus appears to be more commonly 
affected by these pathologies whilst the prenatal ultrasonographic feature in a 
female fetus is often associated with a more complex pathology (e.g. persistent 
cloaca or megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)).  
 
Congenital LUTO may be associated with chromosomal (most common trisomy 
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13 and 18) and monogenic abnormalites especially if extra-urological anomaly is 
present. The risk of chromosomal abnormality is approximately 15% in fetuses 
with ‘megacystis” noted on ultrasound (8); with highest rates with a measured 
fetal longitudinal bladder length of 7-15mm compared to those >15mm at 10-14 
gestational weeks (23.6% versus 11.4%) (9). In addition, congenital bladder 
neck obstruction may be associated with submicroscopic chromosomal 
anomalies, pathologic copy number variants and genetic variants identified by 
microarray and genome sequencing (10). “Prune-Belly syndrome” is a relatively 
rare congenital anomaly sequence characterized by severe megacystis, 
hydronephrosis, deficient abdominal wall musculature and bilateral 
undescended testes (in males) (11). A high prevalence of non-urological 
anomalies (up to 70%) is noted and again ‘prune belly syndrome’ may be 
associated with chromosomal abnormalities and single gene abnormalities 
(ACTA2 gene modification) (12,13). MMIHS almost exclusively affects female 
fetuses and is characterized by prenatal ultrasound dilation of both the distal 
bowel and bladder, with a primary abnormality of the smooth musculature 
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(heterozygous ACTG2 gene missense variants are reported, with a mutation in 
the actin genes) (14). The prognosis of both prune belly syndrome and MMIHS 
are very poor.  
 
 
III) Diagnosis of LUTO 
LUTO can be detected by late first and second trimester of the pregnancy by 
screening ultrasonography (15). Differentiation of obstructive and 
non-obstructive aetiologies (e.g. vesicoureteric reflux) on prenatal sonography is 
challenging as both having similar ultrasound appearances. Whilst challenging, 
there are emerging clinical algorithms that appear to aid prognostic case 
selection for consideration of fetal therapy (see below). 
 
Enlarged fetal urinary bladder caused by obstruction can be detected by 
ultrasonography after 10 weeks of gestation when the fetus starts to produce 
urine (16). In the first trimester, megacystis is usually defined as longitudinal 
bladder diameter ≥7mm (8). In a recently published retrospective series of 541 
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cases of megacystis from the Netherland there was an even more heterogenous 
description of underlying pathologies. A final diagnosis was made in 418 cases. 
Investigation indicated that 53% (222/418) were isolated LUTO, 33% (136/418) 
had genetic, chromosomal or structural anomalies (such as trisomy 13/18/21, 
Turner syndrome, 22q11 microdeletion, VACTERL syndrome, cloacal 
malformation, overgrowth syndrome, etc.), and 14% (60/418) were normal or 
having isolated urological abnormality (vesicoureteric reflux or duplex colleting 
system) (17). Therefore, megacystis is not always associated with LUTO and 
serial ultrasound examinations allow identification of those cases with 
“spontaneous resolution” of the visualized bladder enlargement with 
investigation allowing triage and selection of isolated cases of posterior urethral 
valves most amenable to prenatal intervention. The chance of spontaneous 
resolution depends on the longitudinal bladder length. With the length of 
7-15mm at 10-14 gestational weeks, 90% fetuses with a normal karyotype will 
resolve before 20 gestational weeks, while regression is unlikely for bladder 
length >15mm (9, 18). Another national study from the Netherlands shows 
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spontaneous resolution is more likely when the longitudinal bladder length is 
<12mm for megacystis presented before 18 weeks of gestation (19). Associated 
ultrasonographic features of nuchal translucency >95th centile and umbilical 
cord cysts could be unfavourable factors for spontaneous regression of 
megacystits, and suggest complex megacystis and urethral atresia respectively 
(20). The high spontaneous resolution rate without urological consequence in 
first trimester megacystis can be explained by the autonomic innervation of 
bladder and appearance of smooth muscle occurring after 13 weeks of gestation 
(21). Transient bladder distention in early pregnancy could be physiological as 
there is no contractile tissue within the bladder (9). Persistent megacystis from 
first trimester could represent LUTO. 
 
In the second and third trimester, the obstruction at the level of bladder neck 
leads to the classical ultrasonographic features of proximal dilatation of fetal 
urethra, enlarged urinary bladder (megacystis) and hydronephrosis (bi- or 
unilateral) (15) (Figure 1). Oligohydramnios and renal dysplastic change (either 
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macro or microcystic change in the renal parenchyma) are common additional 
features, depending on the degree of obstruction. The definition of megacystis in 
second and third trimester becomes variable but failure to empty an enlarged 
fetal urinary bladder over a period of 45 minutes or longitudinal diameter (in 
millimeter) greater than gestational age in weeks plus twelve are often accepted 
criteria (8). Both non-obstructive uropathy and LUTO can present as megacystis 
in the second and third trimester (22). A ‘keyhole sign’ can be seen if obstruction 
is at the bladder neck causing dilatation of the posterior urethra (Figure 1). 
Previous studies found this ultrasonographic sign very specific to LUTO 
especially in a fetus with posterior urethral valves (23, 24). However, a 
retrospective study showed that it was only present in 51.6% of fetus with 
proven posterior urethral valve and could be seen in 34.8% of other 
non-obstructive pathologies including vesicoureteric reflux and primary 
megaureter (25). Another retrospective study also demonstrated poor specificity 
of 48% to LUTO (26). This false positive finding could be explained by the 
distension of the lower portion of the urinary bladder, rather than the posterior 
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urethra, due to detrusor instability and bladder - sphincter dysynergy (24). 
Similarly, hydronephrosis may be present on prenatal ultrasonographic 
examination in 88% of LUTO and 79% of non-obstructive uropathy (26), and 
therefore cannot differentiate the underlying aetiology and could represent 
obstructive processes as well as those of severe renal reflux.  
 
The performance of prenatal ultrasonography to identify LUTO remains 
unsatisfactory, even with combination of ultrasonographic signs of megacystis 
(24, 25), dilated posterior urethral value (23, 24) thickened bladder wall (23-25), 
dilated ureters (24), oligohydramnios /anhydramnios (24, 25) and abnormal 
renal parenchyma (macrocystic and/microcystic change) (23, 24). The sensitivity 
was only around 51% and around one quarter of prenatal cases suspicious of 
LUTO were normal at birth or reclassified to other non-obstructive uropathies, of 
which vesicoureteric reflux was the commonest, after postnatal examination (6, 
7). In the Netherlands, a “clinical scoring system” has been derived from a 
retrospective national cohort of 143 cases of suspected LUTO after 18 weeks of 
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gestation. These data have recorded the degree of bladder distension, bilateral 
ureteral diameters, amniotic fluid status (maximal deepest vertical pool depth), 
fetal sex and fetal gestational age of referral as a numerical score (Table 1). A 
score of 4 was given for bladder volume >35cm3/urinary ascites, 
oligohydramnios/ anhydramnios, male fetus and referral before 28 gestational 
weeks respectively, and score of 1.3 for each millimeter of ureteral dilatation. A 
cut-off of >9.5 was suggested to differentiate the genuine obstructive uropathy 
from non-obstructive cause with 78% sensitivity and 79% specificity (Figure 2) 
(26). The weakness of these data is the exclusion of pregnancies where parents 
opted for termination of pregnancy.  
 
Other imaging modalities, such as magnetic resonance imaging (MRI) have 
demonstrated some promise as a diagnostic imaging tool (27). Prenatal MRI may 
be performed in female fetus to assess urogenital obstructive anomaly and give 
additional information on the presence of microcolon, dilated esophagus and 
absence of abdominal musculature to suggest megacystis-microcolon-intestinal 
hypoperistalsis syndrome (28, 29). Three-dimensional virtual fetal cystoscopy by 
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MRI may provide another mean of fetal urinary tract evaluation (30) by virtual 
visualization of the urethal lumen, distended bladder and hydroureter, therefore 
potentially suggesting the underlying etiology non-invasively. However, in-utero 
MRI was mostly done during the third trimester and therefore its role in prenatal 
diagnosis of LUTO in first and second trimester is uncertain, which should be 
further explored in view of its non-invasive nature.  
 
IV) Prognostic evaluation and selection for fetal therapy 
The prognosis of congenital LUTO depends on the underlying pathology, severity 
of the obstruction, chromosomal abnormality and other associated structural 
anomaly. Invasive prenatal diagnostic test should be performed for genetic 
evaluation (8-14). A Detailed structural scan should be performed. A fetus with 
isolated prenatally confirmed LUTO with early onset oligohydramnios yet with 
reversible fetal renal function would benefit most from fetal intervention.  
 
a) Prognosis by ultrasonography 
In a systemic review, performed by our group, that included 13 studies and 215 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15
women with confirmed LUTO postnatally, the most predictive ultrasonographic 
parameters at diagnosis for postnatal renal function were: a) renal cortical 
appearance (renal parenchyma echogenicity or cystic change within the renal 
cortex), with sensitivity of 0.57 (95% CI 0.37–0.76) and specificity of 0.84 (95% 
CI 0.71–0.94), and b) the presence of oligohydramnios, with sensitivity of 0.63 
(95% CI 0.51–0.74) and specificity of 0.76 (95% CI 0.65–0.85) (31). However, no 
consistent definition of oligohydramnios was present in many of the included 
studies with many reporting this subjectively. A retrospective study analyzing 51 
boys born with posterior urethral valve, using amniotic fluid of less than 5cm or 
the fifth centile to define oligohydramnios, gave a positive likelihood ratio of 17.0 
(95% CI 2.4-122) to predict postnatal renal impairment (32). Renal cortical 
changes likely represent an irreversible in-utero renal damage, which leads to 
decrease fetal urinary output causing oligohydramnios. On the other hand, being 
a severe end of LUTO spectrum, oligohydramnios could also be due to complete 
blockage at bladder neck before the development of in-utero renal failure. 
Therefore, oligohydramnios could not be used alone to guide clinical 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16
management because it could not differentiate the women with fetus in early 
stage of congenital LUTO who may benefit from intrauterine treatment to salvage 
the fetal renal function. Moreover, normal amniotic fluid at presentation could 
not guarantee normal postnatal renal function and 32% required renal 
replacement therapy after delivery (33).  
 
Fetal bladder-refilling time has been purposed to assess the cortical renal 
function prospectively (34). Using the percentage of fetal bladder refilling (fetal 
bladder volume 48 hours after vesicocentesis − fetal bladder volume before 
vesicocentesis)/(fetal bladder volume before vesicocentesis)×100, a cut of <27% 
could predict the residual renal function and the chance of progression to 
in-utero renal failure with 80% sensitivity and 75% specificity. In this cohort, 
eight fetuses developed in-utero renal failure, including four fetuses receiving 
fetal therapy with favorable urinary biochemistry, six died within first 24 hours 
of life and the two survivors required dialysis within the first week of life (34). 
Combining the gestational onset of oligohydramnios and fetal bladder volume, 
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Fontanella et al. stratified LUTO into mild (normal amniotic fluid at 26 weeks), 
moderate (bladder volume <5.4cm3 and normal amniotic fluid at 20 weeks) and 
severe (bladder volume ≥ 5.4cm3 or oligohydramnios before 20 weeks) forms; 
the risk of perinatal mortality and postnatal renal dysfunction were 9% and 11% 
in mild; 26% and 31% in moderate; and 55% and 44% in severe cases 
respectively (35).  
 
b) Prognosis by fetal urinalysis 
Examination of fetal urine may provide valuable information on the degree of 
in-utero renal impairment and postnatal prognosis. Serial assessment by 
vesicocentesis every 48 hours is recommended, as again this in theory assesses 
the prospective ability of the kidney to produce and concentrate urine (36). 
Theoretically, the first urine sample obtained by vesicocentesis represents the 
urinary stasis for prolonged period of time and the second urinary sample could 
mean the chronic urinary collection from upper urinary tract. The third urine 
sample should be fresh urine excreted by fetal kidney and truly reflect the 
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in-utero renal function (36). Fetus with salvageable renal function should 
demonstrate decreasing urine values and the third urine sample fall below the 
threshold value (<100mg/dl for sodium, <90mg/dl for chloride, < 200mOsm/L 
for osmolality, < 8 mg/dl for calcium, and < 20mg/dl for total protein, β-2 
microglobulin <6mg/L) (36, 37). Unfavorable first sample could improve with 
sequential analysis (36). Therefore, using the first urine sample for clinical 
management may misclassify the in-utero renal function.  
 
A systematic review, including 23 studies and 572 women with prenatal 
ultrasonographic evidence of LUTO, evaluated the use of urinary analyte to 
predict postnatal renal function (38). The two most useful urinary analytes were 
noted to be urinary calcium >95th centile for gestation (likelihood ratio positive 
6.65; 95% CI 0.23–190.96; likelihood ratio negative 0.19; 95% CI 0.05–0.74) and 
sodium >95th centile for gestation (likelihood ratio positive 4.46; 95% CI 1.71–
11.6; likelihood ratio negative 0.39; 95% CI 0.17–0.88). However, there was 
massive heterogeneity noted between studies in the review and in many cases 
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the cohort studies were small and retrospective. Therefore, none of the fetal 
urine analytes investigated yielded sufficient clinically significant accuracy to 
predict postnatal renal dysfunction. Furthermore, not all included studies were 
using serial vesicocentesis for assessment and fetuses with presumed LUTO were 
included, which mean some fetuses may turn out to have non-obstructive 
uropathy. New urinary peptide might help to predict the chance of postnatal 
renal impairment by higher sensitivity and specificity than traditional fetal 
urinalysis (39), which requires further validation.  
 
c) Selection of suitable candidates for fetal therapy – Combination of 
prognostic factors and a staging system 
The aim of fetal therapy is to prevent the complications from congenital LUTO, 
which are pulmonary hypoplasia leading to neonatal mortality, bladder 
dysfunction and development of postnatal renal failure requiring renal 
replacement therapy after birth. Detailed counseling of the parents before fetal 
therapy is crucial to meet reasonable expectations. For fetus with no evidence of 
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fetal renal failure, the objective is to preserve renal function in-utero, and prevent 
mortality and postnatal renal failure. For fetus with features of in-utero 
irreversible renal dysfunction, the role of fetal therapy is controversial, as the 
infant would require long-term dialysis or renal transplantation after birth and 
termination of pregnancy may be an option. However, as discussed, it remains 
challenging to estimate the fetal renal function. Since there is no significant 
association between ultrasonographic fetal renal appearance and urine 
biochemistry (40) and they may play an independent role in predicting postnatal 
renal function, prognostic evaluation should therefore be based on combination 
of different parameters from prenatal ultrasonography and fetal urinalysis. A 
staging system is proposed to guide the clinical management of congenital LUTO 
(Table 2) (41-43). A single centre retrospective study using this staging system 
showed good prognosis in five stage I disease with 100% survival and no end 
stage renal failure at 2 years (43). The survival and end stage renal failure rate at 
two years were 86% and 18% in stage II disease and 43% and 100% in stage III 
disease respectively. All fourteen women with stage II disease and three out of 
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seven women with stage III disease received fetal intervention. A significant 
limitation of this study was that postnatal diagnosis was not available and there 
were no control group in stage 2 and stage 3 diseases. This staging system is 
good in term of using combination of different prenatal parameters of serial 
assessment and offering suggestion for clinical management. The main limitation 
is that it does not incorporate the underlying primary pathology, which would 
affect the outcome ultimately. Adjustment in this staging system with the 
previous mentioned scoring system (26), MRI (27-30) and urinary peptide (39) 
assessment may be necessary in future and prospective evaluation with a control 
group would be meaningful. 
 
V) Fetal intervention  
a) Vesicoamniotic shunting 
The placement of a vesicoamniotic shunt was initially described in the 1980s by 
Charles Rodeck theoretically, allowing free fetal urinary drainage from the 
urinary bladder (obstructed at the bladder neck) in order to relieve the pressure 
within the urinary system to prophylactically protect the kidneys against renal 
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damage.  In addition, the placement of this “fetal suprapubic catheter” would 
restore normal amniotic fluid preventing pulmonary hypoplasia. It is a minimally 
invasive procedure, which involves ultrasonography-guided insertion of double 
pigtail catheter (usually a Rocket™ shunt) into the fetal urinary bladder 
(proximal end) and the amniotic cavity (distal end). This is usually performed 
with maternal sedation and with local anesthesia (Figure 2). A 16-gauge Rocket™ 
introducer needle is passed through the maternal abdomen, uterus and amniotic 
cavity under continuous real time ultrasound. The fetal abdominal wall and 
urinary bladder are then punctured using this trocar. The double pigtail catheter 
(Rocket™) is deployed with the distal end in the fetal urinary bladder and the 
proximal end is deployed in the amniotic space. Amnioinfusion of warmed (20°C) 
Physiological/ Hartmann’s solution may be necessary in case of anhydramnios to 
facilitate the procedure and to create an echolucent ‘operative window’. There 
are now several designs of pigtail catheters and each may have different success 
rates.  
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The only randomized controlled trial to evaluate the use of vesicoamniotic shunt 
versus conservative management was the Percutaneous vesicoamniotic shunting 
versus conservative management for Lower Urinary Tract Obstruction (PLUTO) 
trial (44). Women, who were pregnant with a male fetus showing 
ultrasonographic features of LUTO (visualization of enlarged bladder, dilated 
proximal urethra, presence of hydronephrosis and cystic parenchymal renal 
disease), were randomized to receive either percutaneous vesicoamniotic shunt 
or conservative management. Unfortunately, with a planned sample size of 150, 
the trial was prematurely stopped after recruiting 31 women due to poor 
recruitment rate. Clinicians would choose to use either a Rocket or Harrison 
shunt. In the analysis upon actual treatment received, 15 women received 
vesicoamniotic shunt and 16 women were managed conservatively, there were 
11 and 13 live born, two and ten neonatal death within 28 days respectively. All 
neonatal deaths were secondary to complication of pulmonary hypoplasia. A 
statistically significant effect of vesicoamniotic shunting over conservative 
management was found on perinatal survival <28 days (RR 3.20; 95% CI 1.06–
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9.62; P = 0.03) in actual-treatment-received analysis. Renal impairment was 
noted in majority of the survivors in the vesicoamniotic shunt group. 
Complications were common and seen in six fetuses (40%) resulting in one 
miscarriage and three termination of pregnancy due to guarded prognosis. The 
complications were spontaneous rupture of membranes, and shunt dislodgement 
or blockage. Furthermore, the long-term outlook of the survivors in the 
intervention group was not promising. Only seven were alive at two years of age, 
and five of them had renal impairment. Within the PLUTO RCT, there were no 
prognostic indicators for fetal therapy. Instead, a pragmatic clinical approach was 
used based on clinician equipoise. A parallel non-randomized registry included a 
variable case mix and thus logistic regression analysis was able to identify that 
gestation at diagnosis < 24 weeks and liquor volume were poor prognostic 
indicators. 
 
A systematic review of nine studies, including the PLUTO RCT, involving 246 
fetuses compared 112 vesicoamniotic shunt with 134 conservative management 
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(45). Cases of termination and chromosomal anomalies were excluded. 
Congenital LUTO was defined by presence of enlarged fetal bladder and bilateral 
hydronephrosis. Although a better perinatal survival was observed after 
vesicoamniotic shunt insertion, there was no difference in postnatal survival at 
6-12 months and at 2 years. The postnatal renal function was not different in the 
two groups. Confirmation of LUTO was not specified in some studies. Again, 
proper prognostic prioritization before subject recruitment was not formally 
done in most studies. There was only one randomized controlled trial and 
therefore possible selection bias.  
 
The urinary bladder function was not evaluated in most of the interventional 
studies using vesicoamniotic shunt. A long term follow up study, at mean age of 
54.3 months after fetal vesicoamniotic shunt insertion, reported 75% bladder 
augmentation in survivors of posterior urethral valve and 28.5% of total 
survivors needed intermittent catheterization (46). Normal bladder filling and 
emptying cycle could be essential to perverse the urinary bladder compliance. In 
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animal model, the abolishment this cycle after putting a vesicoamniotic shunt in 
lamb without LUTO can also create a fibrotic bladder with poor compliance after 
delivery (47). Putting a low-pressure valved vesicoamniotic shunt could 
theoretically preserve bladder compliance with less associated muscle fibrosis 
(47) but no human study has so far been described using this type of shunt.   
 
b) Fetal cystoscopy 
Postnatally, posterior urethral valves are treated with cystoscopic fulguration 
thus the use of the same procedure prenatally may have some advantages. The 
development of <2mm endoscope allows fetal cystoscopy to be performed in 
early pregnancy (Figure 4). he major advantages of fetal cystoscopy over 
vesicoamniotic shunt are direct visualization of the bladder neck providing 
diagnostic identification of the underlying pathology and thus specific 
therapeutic treatment where available (48). The diagnostic information obtained 
may again aid prognostic counseling to the women. In addition, relieving the 
obstruction during fetal life could allow a more ‘physiological’ drainage of the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 27
urine and thus normal bladder muscle development.  
 
Fetal cystoscopy can be performed under regional anesthesia or maternal 
sedation with local analgesia (48-50). Fetal sedation is achieved by 
intraumbilical or fetal intramuscular injection to the arm/leg of fentanyl and 
pancuronium under ultrasonographic guidance, using a 22-gauge needle. A 
2.2-3.3mm curved sheath is inserted through the maternal abdomen, uterus, 
amniotic space and fetal urinary bladder under ultrasonographic guidance 
(Figure 3). The fetoscope is advanced toward the bladder neck with a dilated 
posterior urethra. Transurethral stenting of urethral stenosis or ablation of the 
posterior urethral valve can be performed. Clearance of obstruction can be 
confirmed by water injection through the cystoscopy and observing the flow 
along the urethra under power Doppler study. It is a technically demanding 
procedure and often visualization of the proximal urethra is difficult or 
impossible due to the angle of the bladder axis to the urethral axis. There is a 
reported high risk of preterm pre-labour rupture of membranes and this is a 
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significant complication (23%) (50). In addition, cohort studies have recorded 
complications such as ‘false tract’ formation and iatrogenic urological fistula 
formation after ablation (around 10%) (49). A curve trocar and insertion at the 
upper fetal bladder (different from vesicoamniotic shunt) is necessary to 
visualize the fetal bladder neck, which may also lead to umbilical vein laceration 
(50). 
 
A systematic review of the cohort studies of fetal cystoscopy for the investigation 
and treatment of LUTO identified four papers with a total of 63 subjects (48). 
Fetal cystoscopy altered the prospective prenatal diagnosis in 25–36% of cases 
and the sensitivity was 83-100% for diagnosing posterior urethral valve and 
100% for urethral atresia. Improvement of perinatal survival was observed in 
fetal cystoscopy group compared with no intervention (Odd ratio 20.51; 95% CI 
3.87–108.69) but not when compared with vesicoamniotic shunt (Odd ratio 1.49; 
95% CI 0.13–16.97). Overall, a small number of studies, mainly retrospective 
with small sample size and a lack of randomized controlled trial hinder these 
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conclusions. 
 
A retrospective cohort study of 48 cases of confirmed LUTO with normal 
karyotype showed the risk of fetal demise was 4.2% after fetal cystoscopy and 
neonatal mortality rate was 22.9% (50). The survival rate and infants with 
normal function were 37.5% and 77.8% at one year of age, and 34.8% and 75% 
at two years of age respectively. Outcomes of urethral atresia and stenosis were 
extremely poor, with majority of women opted for termination of pregnancy 
(72%), four neonatal death (22%) and only one survivor whom received 
transurethral stenting for urethral stenosis. For fetus with posterior urethra 
valve, there was 20% recurrence of LUTO in which half required additional fetal 
therapy, 13.3% risk of urological fistulas formation and 3.3% risk of fetal 
umbilical vein laceration. The survival rate and infant with normal renal function 
at one year and two years of age were around 55% and 75% respectively.  
 
c) Fetal cystoscopy versus vesicoamniotic shunt 
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There is no randomized controlled trial to allow head to head comparison 
between these two fetal interventions. Ruano et al. performed a retrospective 
analysis of 111 male fetuses with prenatal presumed LUTO (51). 34 fetuses 
received fetal cystoscopy, 16 fetuses had vesicoamniotic shunt and 61 controls 
had no fetal therapy. Fetal intervention, either by fetal cystoscopy and 
vesicoamniotic shunt, was significantly associated with better survival when 
compared to control group (adjusted relative risk (ARR), 1.86 (95% CI, 1.01–3.42; 
P=0.048) and ARR, 1.73 (95% CI, 1.01–3.08; P=0.04) respectively). A trend of 
favoring normal renal function was observed in the fetal cystoscopy group (ARR, 
1.73 (95% CI, 0.97–3.08; P=0.06)) but not in the vesicoamniotic shunt group. For 
fetus with posterior urethral valve confirmed after delivery, fetal cystoscopy 
improved renal function at 6-month (ARR, 2.66 (95% CI, 1.25–5.70; P=0.01)), 
while this effect was not seen in the vesicoamniotic shunting group (ARR, 1.03 
(95% CI, 0.49–2.17, P=0.93)). Shunt obstruction or migration occurred in 31.3% 
in vesicoamniotic group and urological fistula happened in 8.8% of fetal 
cystoscopy group. A randomized controlled trial is proposed to compare both 
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interventions in LUTO (NCT01552824).  
 
d) Minimizing complications 
The type of shunt may affect the chance of shunt dislodgement. The Harrison 
Fetal Bladder Stent was associated with a higher dislodgement rate than the 
Rocket® KCH™ Fetal Bladder Catheter (78% versus 30%) (52). Choosing the 
optimal instrument and energy may prevent urological fistula formation during 
fetal cystoscopy (49). A true curved sheath allows adequate access to the fetal 
bladder neck and subsequent correct angle to apply laser to the posterior 
urethral valve. The use of lowest effective energy during treatment and fetal 
anesthesia can decrease the chance of inadvertent peripheral tissue damage. 
Similar to other fetal intervention (53), operators’ experience could increase the 
chance of success and decrease complication (50).  
 
VI) Clinical approach to LUTO – from screening to management 
A suggested clinical approach to LUTO first detected during first and second 
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trimester of pregnancy is presented in Figure 5. Conservative management with 
serial ultrasonographic monitoring is recommended for LUTO with normal 
amniotic fluid volume and renal appearance. Option of termination of pregnancy 
may be discussed if there is sign of in-utero renal failure, especially before 24 
weeks of gestation, by the presence of oligohydramnios/ anhydramnios and renal 
dysplastic feature, which indicates high chance of pulmonary hypoplasia and 
postnatal renal failure. 
 
LUTO with oligohydramnios and no obvious ultrasonographic feature of 
irreversible renal damage may benefit from fetal intervention and requires 
further evaluation by detailed structural scan, invasive test for genetic study and 
serial fetal urinalysis in order to determine the likelihood of a true obstructive 
uropathy and estimate the remaining in-utero renal function. Fetal therapy could 
be discussed in those with signs indicative of a favorable prognosis to prevent 
complications from LUTO (stage 2 +/- stage 3). In fetus with in-utero renal failure 
(stage 4), vesicocentesis and fetal cystoscopy cannot restore amniotic fluid 
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volume (as decrease fetal urine output) and renal damage has already occurred. 
Therefore, vesicoamniotic shunt and fetal cystoscopy are not recommended. The 
management is complex and controversial if the parents consider continuation of 
the pregnancy. Although repeated amnioinfusion may be a treatment option 
aiming to prevent pulmonary hypoplasia (54), concerns remain on the potential 
procedural related risk of maternal infection, preterm prelabour rupture of 
membranes and preterm delivery, which further worsen the maternal and 
neonatal prognosis (55, 56). In addition, significant neonatal morbidity and 
mortality is expected, even after repeated amnioinfusion, due to perinatal renal 
failure (56). Furthermore, the optimal gestational age to initiate, frequency of 
amnioinfusion, short-term and long-term morbidities and quality of life after 
treatment are not clear (55). The efficacy to prevent hypoplasia is also not known. 
However, the rapid improvement in the management of neonatal renal failure 
improve the outlook of these babies, which may make pulmonary palliation 
in-utero and neonatal renal replacement therapy (dialysis or transplantation) an 
feasible option in future (56). Therefore, detailed counseling and proper 
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evaluation under research setting is required if active intervention is sought.  
 
LUTO presenting in the third trimester is uncommon due to the widely available 
prenatal screening ultrasonography, which permits early detection of LUTO. First 
presentation at this gestation may represent a milder disease with incomplete/ 
transient obstruction (likely normal in-utero renal function) or severe LUTO 
when early screening ultrasonography is not available (likely damaged fetal 
kidneys). Fetal therapy is usually not indicated in both situations.  
 
If there is a need to consider fetal intervention for LUTO in the third trimester 
especially after 34 weeks of gestation, one needs to balance the risk of preterm 
delivery by fetal therapy, which may add extra burden, and on-going renal injury 
by expectant management. It seems reasonable to consider delivery at term if 
there is a concern of possible on-going renal damage. Earlier elective delivery to 
prevent renal complication is controversial.  
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 35
VII) Summary  
Congenital LUTO can be detected by prenatal first and second trimester 
screening ultrasonography. It can lead to significant mortality and long-term 
morbidity, which may be ameliorated by fetal therapy. The success of fetal 
therapy depends heavily on proper selection of suitable candidates, which is 
currently hindered by the difficulty in prenatal identification of underlying 
etiology (obstructive or non-obstructive uropathy) and the lack of reliable 
prenatal markers to predict the in-utero course and subsequent renal 
impairment after birth. New advances in clinical scoring system (26), in-utero 
renal function assessment by fetal bladder refilling (34) and fetal urinary peptide 
assessment (39), non-invasive evaluation by MRI (27-30) and staging system 
(41-43) would definitely refine the management of congenital suspected LUTO. 
Vesicoamniotic shunt and fetal cystoscopy are the main fetal therapies for LUTO. 
These interventions could improve neonatal survival rate but, unfortunately, 
have failed to demonstrate long-term renal benefits. Fetal cystoscopy may be 
more appealing in view of the advantages over vesicoamniotic shunt, but is 
technically challenging. A well-designed and coordinated randomized controlled 
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trial is certainly needed to reveal the role of fetal therapy in LUTO.  
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Practice points 
- Congenital non-obstructive uropathy can share similar prenatal 
ultrasonographic characteristic with obstructive uropathy. 
- Prognostic estimation is essential before fetal therapy 
- Fetal intervention can improve perinatal survival but survivors still have a 
high rate of renal impairment.  
 
Research agenda 
- Non-invasive modality for prenatal diagnosis of congenital lower urinary 
tract obstruction 
- Use of magnetic resonance imaging, urinary biomarkers and other new 
ultrasonographic markers to estimate in-utero renal function 
- Trials, using a staging system, to evaluate fetal therapy in congenital lower 
urinary tract obstruction  
- Long term outcomes of survivors after fetal intervention 
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Table 1. Clinical scoring system to predict congenital LUTO 
 Score 
Severe megacystis (bladder volume 
>35cm3/urinary ascites) 
4 
Bilateral ureteral diameters 1.3 for each millimeter of ureteral 
dilatation 
Oligohydramnios/ anhydramnios 4 
Male fetus 4 
Referral before 28th gestational weeks  4 
Adapted from Fontanella F, Duin LK, Adama van Scheltema PN, Cohen-Overbeek 
TE, Pajkrt E, Bekker M, Willekes C, Bax CJ, Gracchi V, Oepkes D, Bilardo CM. 
Prenatal diagnosis of LUTO: how to improve diagnostic accuracy. Ultrasound 
Obstet Gynecol. 2017 Dec 20.  
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Table 2 Clinical staging system for management of congenital LUTO 
 Stage I  Stage II  Stage III  Stage IV 
Amniotic fluid Normal Oligohydramnios Anhydramnios/ 
oligohydramnios 
Anhydramnios 
Fetal renal 
appearance on 
ultrasonography 
Normal Normal to 
echogenic 
Echogenic, 
presence of renal 
cyst ± dysplasia 
Bladder refilling > 
27% 48 hours 
after 
vesicocentesis 
Echogenic, 
presence of renal 
cyst and dysplasia 
Bladder refilling ≤ 
27% 48 hours after 
vesicocentesis 
Fetal urinalysis Favourable 
(usually fetal 
analysis not 
indicated) 
Favourable after 
sequential 
sampling 
Unfavourable 
after sequential 
sampling 
Unfavourable after 
sequential 
sampling 
Interpretation - Likely partial/ 
transient 
obstruction 
- Low risk of 
pulmonary 
hypoplasia and 
in-utero renal 
failure 
- Risk of 
pulmonary 
hypoplasia if 
oligohydramnios 
< 24 weeks 
- Likely normal/ 
reversible fetal 
renal function 
- Risk of 
pulmonary 
hypoplasia if 
anhydramnios/ 
oligohydramnios 
< 24 weeks, 
- Possible in-utero 
renal failure 
- Risk of pulmonary 
hypoplasia if 
anhydramnios/ 
oligohydramnios < 
24 weeks 
- Likely in-utero 
renal failure 
Risk and 
prognosis 
Generally good 
prognosis 
Risk of pulmonary 
hypoplasia and 
renal failure 
Risk of neonatal 
death and renal 
failure 
Guarded prognosis, 
high risk of early 
neonatal death  
Management 
(Also see Figure 
5) 
One to two 
weekly 
monitoring 
Vesicoamniotic 
shunt or fetal 
cystoscopy 
Vesicoamniotic 
shunt or fetal 
cystoscopy 
Option of 
termination of 
pregnancy 
? Serial 
amnioinfusion 
Rational of fetal Not indicated Prevent perinatal Prevent perinatal Controversial, 
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intervention mortality and 
postnatal renal 
failure 
mortality but may 
have postnatal 
renal impairment 
expect renal failure 
at birth and 
mortality 
Modified from Ruano R, Dunn T, Braun MC, Angelo JR, Safdar A. Lower urinary 
tract obstruction: fetal intervention based on prenatal staging. Pediatr Nephrol. 
2017;32:1871-1878.  
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Figure 1. Typical prenatal ultrasonographic findings of lower urinary tract 
obstruction. (a) A dilated proximal urethra, known as keyhole sign. (b) Enlarged 
fetal urinary bladder and hydronephrosis. 
Kilby MD, Morris RK. Fetal therapy for the treatment of congenital bladder neck 
obstruction. Nat Rev Urol. 2014;11:412-9.  
 
Figure 2. Receiver-operating curves for prenatal prediction of congenital lower 
urinary tract obstruction (clinical scoring    , classic triad ---) 
Fontanella F, Duin LK, Adama van Scheltema PN, Cohen-Overbeek TE, Pajkrt E, 
Bekker M, Willekes C, Bax CJ, Gracchi V, Oepkes D, Bilardo CM. Prenatal diagnosis 
of LUTO: how to improve diagnostic accuracy. Ultrasound Obstet Gynecol. 2017 
Dec 20.  
 
Figure 3. Prenatal vesicoamniotic shunt placement.  
(a) Schematic illustration of vesicoamniotic shunting. (b) Post-insertion 
ultrasonography, demonstrating correct placement of vesicoamniotic pigtail 
catheter with the proximal end in the bladder and the distal end in the amniotic 
cavity (arrows).  
Adapted with permission from BMJ Publishing Group Limited. Morris, R. K. et al. 
Vesicoamniotic shunting for fetal lower urinary tract obstruction: an overview. 
Arch. Dis. Child Fetal Neonatal Ed. 92, F166–F168 (2007). 
 
Figure 4. Visualization of the fetal bladder neck by fetal cystoscopy. 
(a) An endoscope in a curved sheath was inserted through the maternal 
abdomen and uterus into the fetal bladder allowing direct visualization of the 
fetal bladder neck. (b) Cystoscopic view of a dilated posterior urethra.  
Abbreviations: LF, laser fibre; PUV, posterior urethral valve.  
Permission obtained from Cambridge University Press © Kilby, M. D. et al. (eds) 
Fetal Therapy: Scientific Basis and Critical Appraisal of Clinical Benefits (2012). 
(Provided by Dr Ruano Rodrigo) 
 
Figure 5. Clinical approach to LUTO – from screening to treatment  
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Highlight 
- Congenital non-obstructive uropathy can share similar prenatal ultrasonographic 
characteristic with obstructive uropathy. 
- Prognostic estimation is essential before considering fetal therapy 
- Fetal intervention may possibly improve perinatal survival but survivors still have 
a high rate of renal impairment.  
 
